Aprogen Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
720
- Stock Symbol
-
007460
- Investments
-
7
- Share Price
-
$1.41
- (As of Thursday Closing)
Aprogen General Information
Description
Aprogen Medicines Inc, formerly Aprogen KIC Inc manufactures and maintains plant equipment for the industrial furnace and oven sector. Its business divisions include plant, fired heater, hard facing, and thermal insulation works.
Contact Information
Website
www.aprogen.comCorporate Office
- 545, Dunchon-daero
- Jungwon-gu
- Seongnam, Gyeonggi 13215
- South Korea
Corporate Office
- 545, Dunchon-daero
- Jungwon-gu
- Seongnam, Gyeonggi 13215
- South Korea
Aprogen Stock Performance
As of 12-Nov-2026, Aprogen’s stock price is $1.41. Its current market cap is $31.3M with 22.2M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.41 | $1.46 | $1.19 - $9.56 | $31.3M | 22.2M | 316K | $12.20 |
Aprogen Financials Summary
As of 30-Jun-2026, Aprogen has a trailing 12-month revenue of $95.7M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 319,065 | 463,776 | 400,868 | 445,368 |
| Revenue | 95,711 | 82,897 | 110,019 | 115,169 |
| EBITDA | (79,634) | (85,004) | (57,336) | (52,940) |
| Net Income | (57,558) | (49,329) | (42,566) | (42,540) |
| Total Assets | 437,101 | 498,097 | 414,107 | 461,269 |
| Total Debt | 117,592 | 130,459 | 77,193 | 96,546 |
Aprogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aprogen Patents
Aprogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026221372-A1 | Bispecific protein with improved heterodimer formation rate and preparation method thereof | Pending | 18-Apr-2025 | ||
| EP-4400116-A1 | Pharmaceutical composition containing anti-tnf alpha antibody | Inactive | 16-Sep-2021 | ||
| EP-4400116-A4 | Pharmaceutical composition containing anti-tnf alpha antibody | Inactive | 16-Sep-2021 | ||
| US-20250144022-A1 | Pharmaceutical composition containing anti-tnfalpha antibody | Pending | 16-Sep-2021 | ||
| AU-2022348349-A1 | Pharmaceutical composition containing anti-tnfα antibody | Inactive | 16-Sep-2021 | A61K39/00 |
Aprogen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aprogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Aprogen Investments & Acquisitions (7)
Aprogen’s most recent deal was a PIPE with Aptocrom for . The deal was made on 24-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aptocrom | 24-Jan-2025 | PIPE | Distributors (Healthcare) | ||
| Pangsky | 10-Jan-2025 | PIPE | Entertainment Software | ||
| Apt Neuroscience | 09-Jan-2025 | Secondary Transaction - Private | Alternative Energy Equipment | ||
| Apt Neuroscience | 27-Nov-2024 | PIPE | Alternative Energy Equipment | ||
| Hwail Pharmaceutical | 23-Oct-2024 | PIPE | Other Pharmaceuticals and Biotechnology |
Aprogen ESG
Risk Overview
Risk Rating
Updated September, 30, 2023
50.88 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,421
Rank
Percentile
Construction & Engineering
Industry
of 382
Rank
Percentile
Non-Residential Construction
Subindustry
of 382
Rank
Percentile
Aprogen Exits (1)
Aprogen’s most recent exit was on 24-Jan-2025 from Aptocrom. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Aptocrom | 24-Jan-2025 | Completed |
|
Aprogen FAQs
-
When was Aprogen founded?
Aprogen was founded in 2000.
-
Where is Aprogen headquartered?
Aprogen is headquartered in Seongnam, South Korea.
-
What is the size of Aprogen?
Aprogen has 720 total employees.
-
What industry is Aprogen in?
Aprogen’s primary industry is Biotechnology.
-
Is Aprogen a private or public company?
Aprogen is a Public company.
-
What is Aprogen’s stock symbol?
The ticker symbol for Aprogen is 007460.
-
What is the current stock price of Aprogen?
As of 12-Nov-2026 the stock price of Aprogen is $1.41.
-
What is the current market cap of Aprogen?
The current market capitalization of Aprogen is $31.3M.
-
What is Aprogen’s current revenue?
The trailing twelve month revenue for Aprogen is $95.7M.
-
What is Aprogen’s annual earnings per share (EPS)?
Aprogen’s EPS for 12 months was $12.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
